SAGA Trial Supports Safe Statin Discontinuation in Elderly Primary Prevention

Stopping statins elderly primary emerges as a viable strategy based on new trial evidence showing equivalent survival for adults aged 75 and older without established atherosclerotic cardiovascular disease. All-cause mortality stood at 7.9 percent with continued therapy versus 7.2 percent after stopping statins elderly primary, with the confidence interval for the absolute difference staying within the prespecified non-inferiority margin across three years of follow-up in routine outpatient settings.

Stopping Statins Elderly Primary Trial Design

A pragmatic multicenter open-label study randomized participants across 297 general practitioner offices using a 5:4 allocation ratio to account for expected treatment changes while maintaining power. Analysis focused on eligible individuals randomized within 90 days, applying multiple imputation for missing survival data. These elements align results closely with everyday adherence patterns and reduce distortions from rigid protocols.

Mortality and Safety Outcomes

Death rates remained comparable between arms, including among participants with diabetes who faced roughly triple the mortality risk of non-diabetic peers. Statin cessation produced no excess hazard. Lipid levels rose within three months after stopping statins elderly primary, yet major atherosclerotic events and quality-of-life scores showed no meaningful shifts. Adverse events such as myopathy and cognitive issues occurred at similar frequencies, suggesting limited added safety gain from ongoing use in long-term recipients.

Ad

Implications for Geriatric Deprescribing

Health technology assessment bodies can now factor survival equivalence into coverage decisions for indefinite statin prescriptions in older primary-prevention groups. Shared decision-making protocols may balance the lack of quality-of-life improvements against lower pill burden, optimizing resource use without raising mortality. Economic models of preventive lipid therapy should incorporate stable cardiovascular outcomes and adverse-event profiles when estimating lifetime costs for aging populations. The findings, detailed in the Lancet publication, support individualized approaches that weigh patient preferences and comorbidities. Clinicians can apply these data to reduce unnecessary medication exposure while preserving clinical benefit, particularly as polypharmacy risks grow with advancing age. Statin therapy decisions may further benefit from updated risk models, while diabetes management considerations remain relevant in this population. Further research may explore subgroup responses and long-term adherence trends to refine deprescribing guidelines.